Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Operating Leases (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Operating Leases for 5 consecutive years, with $19322.0 as the latest value for Q1 2025.

  • Quarterly Operating Leases changed N/A to $19322.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $19322.0 through Mar 2025, changed N/A year-over-year, with the annual reading at $243603.0 for FY2023, 36.26% down from the prior year.
  • Operating Leases for Q1 2025 was $19322.0 at Neuphoria Therapeutics, down from $49818.0 in the prior quarter.
  • The five-year high for Operating Leases was $382188.6 in Q2 2022, with the low at $19322.0 in Q1 2025.
  • Average Operating Leases over 4 years is $156514.3, with a median of $89469.0 recorded in 2024.
  • Peak annual rise in Operating Leases hit 36.74% in 2023, while the deepest fall reached 36.74% in 2023.
  • Over 4 years, Operating Leases stood at $382188.6 in 2022, then tumbled by 36.74% to $241774.1 in 2023, then crashed by 79.39% to $49818.0 in 2024, then plummeted by 61.21% to $19322.0 in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $19322.0, $49818.0, and $89469.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.